NCT07132918SuspendedPhase 2
HEARTS Trial for Thoracic Cancers
The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Reason given: Funding issues
Brief summary (registry, in English)
The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart. The main question it aims to answer is whether MRgART affects the heart differently than LINAC. Participants will: * Receive radiation therapy * Undergo MRIs and bloodwork * Complete quality of life questionnaires
- Status (registry)
- Suspended
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 12 Aug 2025
- Start date
- 8 Oct 2025
- Primary completion date
- Mar 2029
- Lead sponsor
- University of Wisconsin, Madison
- Diseases
- Lung cancer, Gastric and esophageal cancer
- NCT number
- NCT07132918
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior thoracic radiotherapy significantly overlapping the heart region
Other illness
- Definitive clinical or radiologic evidence of metastatic disease with life expectancy <12 months
- Severe, active co-morbidity defined as follows: New York Heart Association Functional Classification III/IV are not eligible.
Other
- Contraindications to MRI
Who the study is looking for
- Age > 18 years at the time of consent.
- Dosimetric eligibility criteria met using endpoints from QUANTEC (>10% of heart receives > 25 Gy) as determined through rapid auto-planning
- Participants with histologically or cytologically proven AJCC, 8th edition including:
- Stage IIB, IIIA, IIIB, IIIC, or IV non-operable non-small cell lung cancer
- Limited stage small cell lung cancer, once daily treatment (excluding twice per day fractionation schemes). Stage I-III N0-2 disease esophageal/esophagogastric cancer
- Stage II or III thymoma/thymic carcinoma
- Other cancers in the thoracic region that meet the dosimetric and other clinical trial criteria, for example lymphoma sarcoma.
- Participants must have a course of daily fractionated RT planned of at least 15 treatment fractions, typically ranging from 1.8 to 4 Gy/fraction
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Wisconsin - Madison | Madison | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.